CRIS Current Research Information System

PAOLINI, STEFANIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 11.788
NA - Nord America 11.331
EU - Europa 9.237
AF - Africa 859
SA - Sud America 609
Continente sconosciuto - Info sul continente non disponibili 23
OC - Oceania 18
Totale 33.865
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.171
CN - Cina 3.192
SG - Singapore 3.119
VN - Vietnam 2.960
GB - Regno Unito 2.612
SE - Svezia 1.535
IT - Italia 1.172
DE - Germania 1.101
HK - Hong Kong 623
IN - India 604
FR - Francia 560
RU - Federazione Russa 459
BR - Brasile 430
IE - Irlanda 305
KR - Corea 301
NL - Olanda 294
JP - Giappone 252
ZA - Sudafrica 237
UA - Ucraina 221
TG - Togo 182
EE - Estonia 160
GR - Grecia 160
FI - Finlandia 151
CI - Costa d'Avorio 136
SC - Seychelles 131
CH - Svizzera 118
NG - Nigeria 113
CA - Canada 102
JO - Giordania 98
BG - Bulgaria 88
AR - Argentina 82
IR - Iran 81
PH - Filippine 80
BD - Bangladesh 72
TR - Turchia 57
PL - Polonia 54
BE - Belgio 51
ES - Italia 50
ID - Indonesia 49
IQ - Iraq 47
TH - Thailandia 45
AT - Austria 38
MX - Messico 34
UZ - Uzbekistan 30
PK - Pakistan 27
EC - Ecuador 25
MY - Malesia 24
TW - Taiwan 24
HR - Croazia 23
EU - Europa 19
PY - Paraguay 19
SA - Arabia Saudita 18
AU - Australia 16
CO - Colombia 15
RO - Romania 14
LB - Libano 13
LT - Lituania 13
VE - Venezuela 13
CL - Cile 12
EG - Egitto 11
CZ - Repubblica Ceca 9
KE - Kenya 9
MA - Marocco 9
TM - Turkmenistan 9
AE - Emirati Arabi Uniti 8
PE - Perù 8
RS - Serbia 8
DZ - Algeria 7
KG - Kirghizistan 7
KZ - Kazakistan 7
OM - Oman 7
TN - Tunisia 7
MK - Macedonia 6
MU - Mauritius 6
PT - Portogallo 6
QA - Qatar 6
AL - Albania 5
ET - Etiopia 5
IL - Israele 5
NP - Nepal 5
AZ - Azerbaigian 4
BB - Barbados 4
LV - Lettonia 4
PA - Panama 4
TT - Trinidad e Tobago 4
BA - Bosnia-Erzegovina 3
HN - Honduras 3
JM - Giamaica 3
LU - Lussemburgo 3
SI - Slovenia 3
XK - ???statistics.table.value.countryCode.XK??? 3
CY - Cipro 2
DK - Danimarca 2
GE - Georgia 2
GY - Guiana 2
HU - Ungheria 2
KH - Cambogia 2
KW - Kuwait 2
MD - Moldavia 2
NI - Nicaragua 2
Totale 33.838
Salva come PNG Salva come JPEG
Città #
Southend 2.395
Singapore 2.178
Ashburn 1.163
Chandler 942
Fairfield 924
Dong Ket 720
San Jose 677
Hefei 628
Hong Kong 588
Houston 528
Wilmington 519
Ho Chi Minh City 482
Woodbridge 451
Hanoi 437
Ann Arbor 428
Seattle 421
Beijing 407
Princeton 407
Santa Clara 392
Cambridge 336
Dublin 302
Boardman 277
Seoul 240
Westminster 211
Nanjing 206
Lauterbourg 205
Bologna 192
Tokyo 187
Padova 183
Lomé 182
New York 164
Los Angeles 151
Abidjan 136
Medford 133
Helsinki 127
Milan 113
Dallas 103
Shenyang 100
Jinan 98
Amman 97
Bern 95
Saint Petersburg 95
Frankfurt am Main 90
Berlin 86
Sofia 86
Buffalo 85
Jacksonville 83
Hebei 78
Nanchang 73
Abeokuta 72
Redondo Beach 70
Munich 66
Da Nang 65
Haiphong 65
Changsha 64
Turin 63
São Paulo 60
Bremen 58
Guangzhou 57
San Diego 57
Bengaluru 56
Tianjin 55
Redwood City 53
Shanghai 53
Florence 52
Brussels 50
Zhengzhou 48
Rome 45
Jiaxing 43
Johannesburg 41
Athens 38
Orem 37
Falls Church 33
Hangzhou 33
Haikou 32
London 32
Redmond 32
Hải Dương 31
Baghdad 30
Mülheim 30
Warsaw 30
Biên Hòa 29
Amsterdam 28
Chicago 28
Norwalk 28
Paris 28
Istanbul 27
Phoenix 27
Ningbo 26
Taiyuan 26
Toronto 26
Tongling 25
Grafing 24
Kunming 24
Mahé 24
Falkenstein 23
San Francisco 23
Taizhou 23
Wuhan 23
Can Tho 22
Totale 21.236
Salva come PNG Salva come JPEG
Nome #
Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience 351
A POLYMORPHISM IN THE CHROMOSOME 9P21 ANRIL LOCUS IS ASSOCIATED TO PHILADELPHIA POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA SUSCEPTIBILITY 349
B-cell acute lymphoblastic leukemia as evolution of a 8p11 myeloproliferative syndrome with t(8;22)(p11;q11) and BCR-FGFR1 fusion gene. 342
A NEW SUBSET OF ADULT B CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENT WITH PREDNISONE-INDUCED MONOCYTIC DIFFERENTIATION? 335
Adult "Triple Negative" ACUTE Lymphoblastic Leukemia Genome Wide Characterization 314
A HIGH SENSITIVE NANOFLUIDIC ARRAY IMPROVES THE DETECTION OF RARE COPIES OF BCR-ABL1 TRANSCRIPT IN PATIENTS WITH PHILADELPHIA POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) 313
Chromothripsis in acute myeloid leukemia: Biological features and impact on survival 296
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. 284
Case Report: A Novel Activating FLT3 Mutation in Acute Myeloid Leukemia 276
EFFICACY, FEASIBILITY AND SAFETY OF NELARABINE SAVAGE THERAPY IN ADULT RELAPSED OR REFRACTORY T CELL ACUTE LYMPHOBLASTIC LEUKEMIA (T-ALL) OR LYMPHOBLASTIC LYMPHOMA (T-LBL): THE BOLOGNA EXPERIENCE 272
Activation of nuclear inositide signalling pathways during erythropoietin therapy in low-risk MDS patients 272
Complete paraplegia after nelarabine treatment in a T-cell acute lymphoblastic leukemia adult patient. 267
Efficacy and clinical outcome of Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) patients treated with second generation tyrosine kinase inhibitors (TKIs): The Bologna experience 262
A miRNA screening identifies miR-192-5p as associated with response to azacitidine and lenalidomide therapy in myelodysplastic syndromes 259
CDKN2A/B alterations impair prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia patients. 255
The alteration in key regulator genes of autophagy is mainstream mechanism of therapy resistance and impact prognosis of acute myelogenous leukemia (AML): results from diagnosis genomic analysis on 148 consecutive patients treated with intensive chemotherapy and long-term survival follow-up 255
Blinatumomab Is Safe and Effective in Relapsed and MRD Positive B-ALL CD19+ Patients: The Bologna Compassionate Program Experience 253
Prolonged low-dose azacitidine schedule in high-risk MDS patients: Hematologic and molecular response 252
Alterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML) 248
Susceptibility to Philadelphia-Positive acute Lymphoblastic Leukemia (ALL) Is Associated with a Germline Polymorphism In the ANRIL (CDKN2BAS) Locus. 244
Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia 236
Chromothripsis in Acute Myeloid Leukemia Is Strongly Associated with Poor Prognosis and TP53 Alterations 231
Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia 230
Philadelphia positive (Ph+) acute lymphoblastic leukemia (ALL) patient with breast infiltration 227
Identification of A Pharmacogenomic Profile Associated with High Sensitivity and Low Toxicity to a Combination of Gemtuzumab Ozogamicin Plus Fludarabine, Cytarabine, Idarubicin Regimen In CD33-Positive Acute Myeloid Leukemia (AML) Patients 227
Assessment of liver stiffness measurement and ultrasound findings change during inotuzumab ozogamicin cycles for relapsed or refractory acute lymphoblastic leukemia 227
WHOLE TRANSCRIPTOME DEEP-SEQUENCING IDENTIFIES NOVEL POINT MUTATIONS, GENE EXPRESSION AND ALTERNATIVE SPLICING PROFILES IN BCR-ABL1 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA 226
AZACITIDINE IN MYELODYSPLASTIC SYNDROMES: RETROSPECTIVE EVALUATION OF LONG-RESPONDER PATIENTS 226
MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia 225
Efficacy and Feasibility of Nelarabine Savage Therapy In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) Strongly Indicates the Introduction of a Nelarabine-Based First Line Regimen 223
LOSS OF THE TUMOR SUPPRESSOR GENE CDKN2A/ARF BY GENOMIC DELETIONS IS A FREQUENT EVENT IN ADULT BCR-ABL1 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS AND CONTRIBUTES TO DISEASE PROGRESSION 222
Clonal activation of Akt in low-risk MDS patients with del(5q) treated with lenalidomide 220
Use of a High Sensitive Nanofluidic Array for the Detection of Rare Copies of BCR-ABL1 Transcript In Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (ALL). 219
Efficacy and Feasibility of Nelarabine Savage Therapy In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) Strongly Indicates the Introduction of a Nelarabine-Based First Line Regimen 217
AZACITIDINE FOR HIGH RISK MYELODYSPLASTIC SYNDROMES. RETROSPECTIVE EVALUATION OF TWO DIFFERENT DOSING SCHEDULES 216
AZACITIDINE IN HIGH AND LOW RISK MYELODYSPLASTIC SYNDROMES: RETROSPECTIVE EVALUATION OF 57 PATIENTS TREATED WITH 4 DIFFERENT THERAPEUTIC REGIMENS 215
LOSS OF THE TUMOR SUPPRESSOR GENE CDKN2A/ARF IS FREQUENTLY DELETED BUT NOT MUTATED IN BCR-ABL1-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS 213
Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. 210
The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report 210
First Report of the Gimema LAL1811 Phase II Prospective Study of the Combination of Steroids with Ponatinib As Frontline Therapy of Elderly or Unfit Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia 209
Distinct pattern of alterations in tp53 mutated and wild type acute myeloid leukemia (AML) patients 208
The Inactivation of the Tumor Suppressor Genes CDKN2A/ARF by Genomic Deletions Frequently Occurs and Worsens Prognosis In Adult BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL) Patients 208
Copy number variants signature in two patients with relapsed acute promyelocytic leukemia 204
At the time of diagnosis, Ph cells from both chronic phase chronic myeloid leukemia and acute lymphoblastic leukemia patients already harbour BCR-ABL kinase domain mutations 203
Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters 203
Early Increase of Phospholipase Cbeta1 (PI-PLCbeta1) Gene Expression Predicts Azacitidine Responsiveness in MDS Patients 201
A germline polymorphism in the ANRIL (CDKN2BAS) locus is associated with susceptibility to Philadelphia-positive acute lymphoblastic leukemia (ALL) 201
Deficient necroptosis pathway as a negative prognostic factor in acute myeloid leukemia. 200
ACTIVATION-INDUCED CYTIDINE DEAMINASE IS ABERRANTLY OVEREXPRESSED IN BCRABL1 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA CELLS AND PROMOTES DNA-SINGLE STRAND BREAKS 199
BCR-ABL1 transcript detection in patients with Philadelphia-positive Acute Lymphoblastic Leukemia (ALL) using a new and high sensitive nanofluidic method 199
Impact of infectious comorbidity and overall time of hospitalization in total outpatient management of acute myeloid leukemia patients following venetoclax and hypomethylating agents 198
BCR-ABL1-Positive Acute Lymphoblastic Leukemia Patients Treated with Only TKI Vs Conventional Chemo Plus TKI Therapy Show Similar DNA Alterations At Relapse Targeting Key Regulators of Tumor Suppression, Cell Cycle Control, and Lymphoid/B-Cell Development 198
Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia 194
The Bcr-Abl kinase promotes aberrant expression of spliced oncogenic Ikaros isoforms in Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) patients treated with tyrosine kinase inhibitors 194
Microarray analysis to identifiy novel copy number alterations in acute myeloid leukemia 192
Impact on survival of catastrophic karyotype events in 101 consecutive acute myeloid leukemia (AML) patients: High risk karyotype and chromothripsis 191
A new biomarker of response to 5-azacitidine therapy in MDS and AML patients: SIRPB1 191
SIRPB1 Is a Strong Predictor Biomarker of Response to 5-Azacitidine Therapy in MDS and AML Patients 189
Increased angiogenesis seems to correlate with inferior overall survival in myeloid sarcoma patients 189
EFFICACY AND CLINICAL OUTCOME OF PHILADELPHIA (PH) POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS TREATED WITH SECOND GENERATION TYROSINE KINASE INHIBITORS (TKIS): THE BOLOGNA EXPERIENCE 189
Survival analysis of patients carrying different FLT3 mutations (internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations) in 459 consecutive non M3 newly diagnosed acute myeloid leukemia (AML) 188
Low-dose lenalidomide plus cytarabine in very elderly, unfit acute myeloid leukemia patients: Final result of a phase II study 188
Philadelphia-positive patients who already harbour imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. 188
Dissecting the Molecular Mechanisms of Aneuploidy in Acute Myeloid Leukemia By Next Generation Sequencing 186
SNPs array karyotyping reveals a novel recurrent 20p13 amplification in primary myelofibrosis. 182
Fludarabine, Cytarabine, Idarubicin and Etoposide (FLAIE) schedule is safe and active for young patients with newly diagnosed acute myeloid leukemia (AML): Results of a multicentric phase III Italian study 182
Gemtuzumab-Ozogamicin Containing Regimens As Induction Therapy Give the Highest Complete Remission Rate and the Longest Overall Survival Compared with Other Induction Regimens in Patients with Newly Diagnosed Acute Myeloid Leukemia 182
Molecular and chromosomal alterations: new therapies for relapsed acute myeloid leukemia. 181
Complex karyotype, older age, and reduced first-line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long-term follow-up 180
Ponatinib Is Well Tolerated and Active In Patients With Relapsed/Refractory Philadelphia Positive Acute Lymphoblastic Leukemia (PH+ ALL) and Advanced Phase Of Chronic Myelogenous Leukemia (CML) Harbouring T315I Mutation: The Bologna Experience 179
Very Poor Outcome and Chemoresistance of Acute Myeloid Leukemia Patients with TP53 Mutations: Correlation with Complex Karyotype and Clinical Outcome 178
Saprochaete clavata infections in patients undergoing treatment for haematological malignancies: A report of a monocentric outbreak and review of the literature 178
FROM DIAGNOSIS TO RELAPSE: AN HIGH-RESOLUTION MOLECULAR ALLELOKARYOTYPING ANALYSIS OF PAIRED DIAGNOSIS-RELAPSE SAMPLES IN BCR-ABL1-POSITIVE ALL INDICATES INVOLVEMENT OF ALTERATIONS TARGETING KEY REGULATORS OF TUMOR SUPPRESSION, CELL CYCLE CONTROL, AND LYMPHOID/B CELL DEVELOPMENT 177
Efficacy and clinical outcome of Philadelphia positive Acute Lymphoblastic Leukemia patients treated with second generation tyrosine kinase inhibitors (TKIS): the Bologna experience 176
TP53 Alterations Including Missense Mutations, Aberrant Exon-Junctions and Internal Intron Retentions Are Frequent and May Contribute to MDM2 Antagonist-Resistance in B-Acute Lymphoblastic leukemia 175
EFFICACY AND FEASIBILITY OF NELARABINE SAVAGE THERAPY IN ADULT RELAPSED OR REFRACTORY T CELL ACUTE LYMPHOBLASTIC LEUKEMIA (T-ALL) OR LYMPHOBLASTIC LYMPHOMA (T-LBL): A SINGLE-CENTER EXPERIENCE 175
TP53 mutations are mutually exclusive with FLT3 and NPM mutations in AML patients and are strongly associated with complex karyotype and poor outcome 174
Two or More Chemotherapy Consolidation Courses, Followed By Autologous Bone Marrow Transplantation, and MRD Negativity, Give Long Term Overall Survival in Acute Myeloid Leukemia Patients 173
Signaling pathways and bone marrow microenvironment in myelodysplastic neoplasms 171
Dose increase of imatinib mesylate may overcome acquired resistance in bcr/abl-positive acute lymphoid leukaemia 171
Revealing very small FLT3 ITD mutated clones by ultra-deep sequencing analysis has important clinical implications in AML patients 171
IKZF1 (IKAROS) Deletions Are Independent On BCR-ABL1 Rearrangement and Are Associated with a Peculiar Gene Expression Signature and Poor Prognosis in Adult B-Progenitor Acute Lymphoblastic Leukemia (ALL) Patients. 171
The baseline comorbidity burden affects survival in elderly patients with acute myeloid leukemia receiving hypomethylating agents: Results from a multicentric clinical study 169
Efficacy of Azacitidine in the treatment of adult patients aged 65 years or older with AML 169
Blastic plasmacytoid dendritic cell neoplasm: is it time to redefine the standard of care? 168
SNP array reveals a new deletion of JAK2 in AML patients 168
Cytoplasmic mutated nucleophosmin (NPM1) in blast crisis of chronic myeloid leukaemia. 167
Extramedullary myeloid tumour of the stomach and duodenum presenting without acute myeloblastic leukemia: a diagnostic and therapeutic challenge. 165
Presence or the Emergence of a F317L BCR-ABL Mutation May Be Associated With Resistance to Dasatinib in Philadelphia Chromosome Positive Leukemia 164
Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL 164
THE RS564398, A POLYMORPHISM IN “THE ANTISENSE NON-CODING RNA IN THE INK4 LOCUS”, ANRIL, IS ASSOCIATED TO PHILADELPHIA POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) SUSCEPTIBILITY 161
Azacitidine Low-Dose Schedule In Low-Risk Myelodysplastic Syndromes. Preliminary Results of a Multicenter Phase II Study 161
GENETIC VARIATIONS IN ADH1A AND CYP2E1 STRONGLY AFFECTS RESPONSE AND TOXICITY TO A COMBINATION OF GEMTUZUMAB OZOGAMICIN PLUS FLUDARABINE, CYTARABINE, IDARUBICIN IN CD33-POSITIVE ACUTE MYELOID LEUKEMIA (AML) PATIENTS 160
Use of a high sensitive nanofluidic array for the detection of rare copies of BCR-ABL1 transcript in patients with Philadelphia-positive acute lymphoblastic leukemia in complete response 160
CLONAL ACTIVATION OF AKT IN LOW-RISK MDS PATIENTS WITH DEL(5Q) TREATED WITH LENALIDOMIDE 160
Survival analysis of 409 consecutive patients with newly diagnosed acute myeloid leukemia treated with intensive induction therapy, with or without the addition of gemtuzomab-ozagomicin (GO) 158
Very poor outcome and chemoresistance of acute myeloid leukemia patients with TP53 mutations: Correlation with complex karyotype and clinical outcome 158
HIGH RATE OF COMPLETE HEMATOLOGICAL RESPONSE IN ELDERLY PH+ ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS BY INNOVATIVE SEQUENTIAL USE OF NILOTINIB AND IMATINIB: A GIMEMA CLINICAL TRIAL LAL 1408 157
You have accessAlterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML) 157
Genomic wide microarray analysis identifies novel copy number alterations in adult acute myeloid leukemia 157
Totale 20.928
Salva come PNG Salva come JPEG
Categoria #
all - tutte 88.535
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 88.535
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.303 0 0 0 0 0 0 0 0 0 0 102 1.201
2021/20224.285 463 82 275 431 413 288 71 273 209 331 736 713
2022/20234.321 490 673 227 546 347 326 149 260 690 83 333 197
2023/20241.192 54 194 52 130 85 256 74 65 56 69 88 69
2024/20254.433 192 694 366 299 611 224 401 124 49 373 246 854
2025/202610.292 894 1.124 943 769 1.156 549 1.015 436 2.300 906 200 0
Totale 34.490